Table 2.

Results of different probiotics in clinical trial for CD.

Probiotics	Placebo or other drugs	Number of people	Results	References
Symprove (L. rhamnosus NCIMB 30173, 30174, 30,175 and 30176)	Placebo	61 patients	The same analysis in the CD group showed no statistically significant changes.	(142)
Bifidobacteria, Lactobacillus and Enterococcus	Mesalazine	96 patients	Mesalazine combined with bifidobacteria, lactobacilli, and enterococci capsules is more effective for the treatment of mild active CD.	(140)
S. boulardii	/	Analysis of 92 patients among 154 cases.	S. boulardii can improve CDAI, BMI, serum Hb, and total cholesterol levels, safely and effectively.	(143)
Kefir (Lactobacillus and L. kefiri)	/	45 patients included with 3 voluntarily withdrew.	The experimental group showed a significant decrease in ESR and CRP. The bloating severity significantly decreased, and the wellbeing index increased.	(145)
L. johnsonii LA1	Placebo	98 patients	L. johnsonii LA1 has a poor effect on preventing the recurrence of CD.	(146)
S. boulardii	Placebo	165 patients	Probiotics as an adjunct treatment after standard therapy are not beneficial for maintaining remission.	(144)
LGG	Placebo	75 patients	Probiotics, as an adjunct therapy in routine treatment, are not beneficial for prolonging the time to recurrence.	(147)